Tadalafil - a therapeutic option in the management of BPH-LUTS.

Item

http://www.wikidata.org/entity/Q38171532

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Tadalafil - a therapeutic option in the management of BPH-LUTS.

@en

type

Item

label

Tadalafil - a therapeutic option in the management of BPH-LUTS.

@en

prefLabel

Tadalafil - a therapeutic option in the management of BPH-LUTS.

@en

P1476

Tadalafil - a therapeutic option in the management of BPH-LUTS.

@en

P2093

C C Carson

http://www.w3.org/2001/XMLSchema#string

D G Wong

http://www.w3.org/2001/XMLSchema#string

J Kissel

http://www.w3.org/2001/XMLSchema#string

M Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data.

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Erectile dysfunction and lower urinary tract symptoms secondary to BPH.

Managing enlarged prostate in primary care.

A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting.

Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

P304

94-103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12305

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259347426

http://www.w3.org/2001/XMLSchema#string

P698

24341303

http://www.w3.org/2001/XMLSchema#string